News & Media

Presentations

  • All PRESENTATIONS
  • AZP-3813
  • Eneboparatide (AZP-3601)
All PRESENTATIONS
  • All PRESENTATIONS
  • AZP-3813
  • Eneboparatide (AZP-3601)
Eneboparatide (AZP-3601)

KOL Event on Eneboparatide: A PTHR1 Agonist for Hypoparathyroidism

Eneboparatide (AZP-3601)

Eneboparatide Development Update. ENDO 2023 KOL Event Presentation.

Eneboparatide (AZP-3601)

Treatment of Chronic Hypoparathyroidism with Eneboparatide (AZP-3601), a Novel PTH 1 Receptor Agonist: Results from a Phase 2 trial. ENDO 2023 Presentation.

Eneboparatide (AZP-3601)

Eneboparatide, a novel PTH1 receptor agonist, induces rapid reduction and normalization of urinary calcium in hypoparathyroid patients. ENDO 2023 Poster. 

Eneboparatide (AZP-3601)

Variations in Clinical Practice Patterns for Hypoparathyroidism. ENDO 2023 Poster.

Upcoming events

Date: October 4-7, 2023 (Marseilles, France)

Date: October 11-13, 2023 (Yokohama, Japan)

Date: October 13-16, 2023 (Vancouver, Canada)

Date: November 1, 2023

Date: November 3-4, 2023 (Sterling, VA)

Social Updates

TWITTER

Scroll to Top